Prestige Consumer Healthcare Inc. to Release Fiscal 2023 Fourth Quarter and Year-End Earnings Results
Prestige Consumer Healthcare Inc. (NYSE:PBH) is set to release its fiscal 2023 fourth quarter and year-end earnings on May 4, 2023, before market opening. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss these results. Investors can access the live webcast through the company's Investor Relations page or register for a phone call. A replay of the call will be available for a week post-event. Prestige Consumer Healthcare offers a diverse range of consumer healthcare products including Monistat®, BC®, Dramamine®, and many others, serving markets across the U.S., Canada, Australia, and beyond.
- None.
- None.
TARRYTOWN, N.Y., April 18, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2023 fourth quarter and year-end earnings release on Thursday, May 4, 2023 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
FAQ
When will Prestige Consumer Healthcare release its fiscal 2023 earnings?
What time is the conference call for Prestige Consumer Healthcare's earnings?
How can I access the conference call for Prestige Consumer Healthcare?
